Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Apr 05, 2024 $24.54 $25.26 $24.34 $24.78 850 233
Apr 04, 2024 $25.32 $25.56 $24.75 $24.97 1 208 882
Apr 03, 2024 $25.00 $25.54 $24.34 $24.98 1 163 252
Apr 02, 2024 $26.38 $26.38 $25.07 $25.10 1 894 161
Apr 01, 2024 $27.43 $27.46 $26.60 $27.22 825 016
Mar 28, 2024 $26.98 $28.23 $26.61 $27.51 1 042 955
Mar 27, 2024 $26.50 $27.46 $26.08 $27.02 1 137 446
Mar 26, 2024 $27.19 $27.55 $26.21 $26.26 938 316
Mar 25, 2024 $26.95 $27.29 $26.74 $26.83 700 561
Mar 22, 2024 $27.62 $27.62 $26.83 $26.91 768 565
Mar 21, 2024 $28.37 $28.54 $27.20 $27.65 1 290 272
Mar 20, 2024 $27.60 $28.41 $27.18 $27.78 911 080
Mar 19, 2024 $27.32 $27.95 $27.10 $27.63 1 006 086
Mar 18, 2024 $28.05 $28.05 $27.08 $27.37 1 465 114
Mar 15, 2024 $27.41 $28.32 $27.41 $28.30 1 928 881
Mar 14, 2024 $28.08 $28.47 $27.00 $27.52 2 007 998
Mar 13, 2024 $27.62 $28.88 $27.27 $28.67 1 422 578
Mar 12, 2024 $29.60 $29.70 $27.76 $27.78 1 309 064
Mar 11, 2024 $29.75 $31.10 $29.16 $29.54 1 220 790
Mar 08, 2024 $30.72 $31.98 $29.61 $29.97 951 928
Mar 07, 2024 $30.10 $30.63 $29.42 $30.02 1 032 651
Mar 06, 2024 $30.84 $31.18 $29.52 $29.95 1 555 668
Mar 05, 2024 $31.99 $32.35 $29.89 $30.25 1 777 713
Mar 04, 2024 $32.99 $33.28 $31.70 $32.39 1 547 384
Mar 01, 2024 $32.42 $34.01 $32.31 $32.66 1 950 889
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT